IONIS PHARMACEUTICALS INC's ticker is IONS and the CUSIP is 462222100. A total of 334 filers reported holding IONIS PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is 0.71 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $19,827,899 | +15.4% | 437,123 | +4.3% | 0.01% | +25.0% |
| Q2 2023 | $17,188,000 | +1060233.1% | 418,913 | +823.5% | 0.01% | +700.0% |
| Q1 2023 | $1,621 | -62.8% | 45,363 | -60.7% | 0.00% | -50.0% |
| Q4 2022 | $4,363 | -99.5% | 115,506 | +510.2% | 0.00% | – |
| Q3 2022 | $837,000 | -92.9% | 18,929 | -94.1% | 0.00% | -100.0% |
| Q2 2022 | $11,869,000 | +67.6% | 320,615 | +67.7% | 0.01% | +75.0% |
| Q1 2022 | $7,082,000 | -85.7% | 191,191 | -88.2% | 0.00% | -84.0% |
| Q4 2021 | $49,392,000 | +420.6% | 1,623,138 | +473.8% | 0.02% | +316.7% |
| Q3 2021 | $9,487,000 | -70.1% | 282,854 | -64.5% | 0.01% | -68.4% |
| Q2 2021 | $31,746,000 | -3.4% | 795,842 | +8.8% | 0.02% | -17.4% |
| Q1 2021 | $32,878,000 | +9.6% | 731,264 | +37.8% | 0.02% | +4.5% |
| Q4 2020 | $30,000,000 | +480.3% | 530,589 | +387.0% | 0.02% | +266.7% |
| Q3 2020 | $5,170,000 | +556.1% | 108,957 | +715.0% | 0.01% | +500.0% |
| Q2 2020 | $788,000 | -76.7% | 13,369 | -81.3% | 0.00% | -87.5% |
| Q1 2020 | $3,385,000 | -49.1% | 71,592 | -35.0% | 0.01% | -11.1% |
| Q4 2019 | $6,649,000 | -45.9% | 110,064 | -46.4% | 0.01% | -52.6% |
| Q3 2019 | $12,293,000 | -51.1% | 205,205 | -47.5% | 0.02% | -48.6% |
| Q2 2019 | $25,126,000 | -15.2% | 390,944 | +7.1% | 0.04% | -15.9% |
| Q1 2019 | $29,630,000 | +556.5% | 365,039 | +337.3% | 0.04% | +528.6% |
| Q4 2018 | $4,513,000 | -31.8% | 83,478 | -34.9% | 0.01% | -12.5% |
| Q3 2018 | $6,619,000 | -12.7% | 128,327 | -29.5% | 0.01% | -20.0% |
| Q2 2018 | $7,581,000 | -37.0% | 181,934 | -33.3% | 0.01% | -37.5% |
| Q1 2018 | $12,027,000 | +22.0% | 272,837 | +39.3% | 0.02% | +14.3% |
| Q4 2017 | $9,855,000 | +0.7% | 195,917 | +1.5% | 0.01% | -6.7% |
| Q3 2017 | $9,787,000 | +98.9% | 193,043 | +99.6% | 0.02% | +66.7% |
| Q2 2017 | $4,920,000 | -87.9% | 96,719 | -90.5% | 0.01% | -88.0% |
| Q1 2017 | $40,812,000 | +19427.3% | 1,015,229 | +23105.2% | 0.08% | – |
| Q4 2016 | $209,000 | -99.6% | 4,375 | -99.7% | 0.00% | -100.0% |
| Q3 2016 | $58,855,000 | +34.8% | 1,606,306 | +49.0% | 0.10% | -9.2% |
| Q1 2016 | $43,663,000 | – | 1,078,089 | – | 0.11% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bellevue Group AG | 9,930,245 | $396,117,000 | 3.87% |
| Sicart Associates LLC | 368,409 | $14,696,000 | 3.50% |
| Camber Capital Management LP | 2,000,000 | $79,780,000 | 2.69% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 181,781 | $7,251,000 | 1.91% |
| SECTOR GAMMA AS | 263,488 | $10,511,000 | 1.86% |
| Parkman Healthcare Partners LLC | 136,380 | $5,440,000 | 1.19% |
| Eversept Partners, LP | 442,000 | $17,631,380 | 1.18% |
| Affinity Asset Advisors, LLC | 75,000 | $2,992,000 | 1.07% |
| TANAKA CAPITAL MANAGEMENT INC | 16,661 | $665,000 | 0.90% |
| Sonora Investment Management, LLC | 168,665 | $6,728,000 | 0.88% |